STUDY

Methotrexate and cyclosporine worked about the same for psoriasis

“Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.” Heydendael VM et al. New England Journal of Medicine. August 2003

Heydendael VM et al. · New England Journal of Medicine · August 2003

Randomized controlled trialPlaque PsoriasisMethotrexateCyclosporine
The finding

In a 16-week trial of 88 people with moderate to severe psoriasis, methotrexate and cyclosporine worked about equally well. The gap between them was small enough to be chance.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized, with blinded scoring. A random process decided who got which medicine. The people doing the scoring did not know which medicine each patient took. Patients and doctors did know, since these are different pills with different dosing.
At a glance

Who was studied and for how long

People
88
44 in each group
Length
16 weeks
Followed for 36 more weeks
Condition
Moderate to severe plaque psoriasis
Thick, scaly patches
Compared
Methotrexate vs cyclosporine
Both taken by mouth
Starting dose
15 mg a week vs 3 mg/kg a day
Adjusted as needed
What they did

How the study worked

88 peoplemoderate to severe plaque psoriasisRANDOMSPLITMethotrexate44 people15 mg a week to startCyclosporine44 people3 mg/kg a day to startMEASURED ATWeek 16by blinded observers88 peoplemoderate to severe plaque psoriasisRANDOMSPLITMethotrexate44 people · 15 mg a week to startCyclosporine44 people · 3 mg/kg a day to startMEASURED ATWeek 16by blinded observers
1. Split at random88 people with moderate to severe plaque psoriasis were randomly put in one of two equal groups.
2. One medicine eachOne group took methotrexate. The other took cyclosporine. Treatment lasted 16 weeks, with 36 more weeks of follow-up.
3. Blinded scoringTrained observers who did not know the medicine scored the psoriasis area and severity index (PASI).
What they found

The results

MethotrexateCyclosporine

Psoriasis score after 16 weeks

Average PASI score. Lower is better. Scores started near 13 to 14.

Methotrexate
5.0
Cyclosporine
3.8
Difference could be chance (p = 0.09)

Stopped treatment because of lab changes

Methotrexate: 12 of 44 people (liver enzymes). Cyclosporine: 1 of 44 (bilirubin).

Methotrexate
27%
Cyclosporine
2%
Cyclosporine's score ended a little lower, but the gap was small enough that it could be chance, so the fair reading is that the two worked about equally well. The doctors' overall ratings, time to remission, and quality of life were also similar. More people on methotrexate had to stop because of liver enzyme increases, and those changes were reversible.
How much to trust it

Strengths and limits

Strengths

  • Randomized head-to-head comparison of two standard psoriasis medicines
  • Scoring was done by trained observers who did not know the medicine
  • Followed people for 36 weeks after treatment

Limits

  • Small: 88 people
  • Patients and doctors knew which medicine was used
  • Starting doses and the dosing plan may not match every clinic
  • Older study: 2003
Moderate confidence. A well-run randomized trial, but small. It shows the two medicines are close, not that one is better.
What it means for you

The takeaway

Close match

For moderate to severe plaque psoriasis, methotrexate and cyclosporine reduced PASI scores by similar amounts. The choice often depends on side effects, other health conditions, and how long you need treatment.

Both need regular blood tests. Your dermatologist can help you pick based on your liver, kidneys, and blood pressure.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

PASI

Psoriasis Area and Severity Index. A score that combines how much skin is affected with redness, thickness, and scaling. Lower is better.

Plaque psoriasis

The most common form of psoriasis, with raised, scaly patches.

Blinded scoring

The people measuring results did not know which medicine each patient took.

p-value

A measure of how likely a difference this size would show up by chance alone. Below 0.05 is the usual cutoff for "probably real."

Original source

Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658–665.

PMID 12917302